RLAY
Relay Therapeutics, Inc. [RLAY] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RLAY Stock Summary
Top RLAY Correlated Resources
RLAY
Top 10 Correlated ETFs
RLAY
Top 10 Correlated Stocks
RLAY
In the News
Relay Therapeutics, Inc. (RLAY) Reports Q3 Loss, Lags Revenue Estimates
Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of -7.04% and 31.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Relay Therapeutics: Best-In-Class Potential PIKCA Mutation Inhibitor
Relay Therapeutics' RLY-2608 is the first pan-allosteric PIKCA mutation inhibitor and has shown promise in preclinical studies, including better safety vs. Piqray (competition). Phase 1 dose escalation data for RLY-2608 is expected in the first half of 2023. The product candidate has the potential to be a blockbuster drug.
7 Unknown Biotech Stocks That Could Rocket in 2023
Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.
Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform
Relay Therapeutics completed what was at the time the 3rd largest Biotech IPO in history in 2020, raising $400m. The company promised to use cutting edge AI driven technology to identify and develop drug targets with a primary focus on precision oncology.
Relay Therapeutics (NASDAQ:RLAY) – Why Relay Therapeutics Shares Are Getting Hammered
Relay Therapeutics Inc (NASDAQ: RLAY) shares are trading lower by 11.33% to $25.54 Tuesday morning after the company priced a roughly 11.32 million share public offering of common stock at $26.50 per share.
Relay Therapeutics (RLAY) Stock: Why It Fell Today
The stock price of Relay Therapeutics (RLAY) fell by 0.72% today. This is why.
Relay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress
Relay Therapeutics to host a conference call on September 12th at 8:00 am E.T. Relay Therapeutics to host a conference call on September 12th at 8:00 am E.T.
Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate Highlights
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report second quarter 2022 financial results and corporate highlights after the close of market on Thursday, August 4, 2022. The company will not be conducting a teleconference in conjunction with its financial results press release.
Relay Therapeutics Announces Timing of Virtual Analyst and Investor Event
CAMBRIDGE, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced registration is open for the virtual analyst and investor event on June 27, 2022 from 8:00 a.m. to 9:00 a.m. ET.
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month at the Cowen 3rd Annual Oncology Innovation Summit on Thursday, June 2, 2022, at 11:30 a.m. ET and at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022, at 5:40 p.m. ET.
RLAY Financial details
RLAY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2020-12-31 | 2021-12-31 |
|---|---|---|---|
| Revenue per share | 1.94 | 0.07 | |
| Net income per share | -1.23 | -8.54 | |
| Operating cash flow per share | -2.4 | -1.75 | |
| Free cash flow per share | -2.45 | -1.83 | |
| Cash per share | 15.91 | 22.48 | |
| Book value per share | 17.91 | 21.07 | |
| Tangible book value per share | 17.91 | 21.01 | |
| Share holders equity per share | 17.91 | 21.07 | |
| Interest debt per share | 0 | 0.54 | |
| Market cap | 2.11B | 863.47M | |
| Enterprise value | 1.67B | 606.25M | |
| P/E ratio | -40.32 | -2.37 | |
| Price to sales ratio | 25.57 | 285.07 | |
| POCF ratio | -20.62 | -11.6 | |
| PFCF ratio | -20.24 | -11.09 | |
| P/B Ratio | 2.77 | 0.96 | |
| PTB ratio | 2.77 | 0.96 | |
| EV to sales | 20.15 | 200.15 | |
| Enterprise value over EBITDA | -34.08 | -1.68 | |
| EV to operating cash flow | -16.25 | -8.15 | |
| EV to free cash flow | -15.95 | -7.78 | |
| Earnings yield | -0.02 | -0.42 | |
| Free cash flow yield | -0.05 | -0.09 | |
| Debt to equity | 0 | 0.02 | |
| Debt to assets | 0.05 | 0.11 | |
| Net debt to EBITDA | 9.16 | 0.71 | |
| Current ratio | 56.49 | 40.14 | |
| Interest coverage | 0 | 0 | |
| Income quality | 1.96 | 0.2 | |
| Dividend Yield | 0 | 0 | |
| Payout ratio | 0 | 0 | |
| Sales general and administrative to revenue | 0.47 | 18.95 | |
| Research and developement to revenue | 1.21 | 57 | |
| Intangibles to total assets | 0 | 0 | |
| Capex to operating cash flow | 0.02 | 0.05 | |
| Capex to revenue | -0.02 | -1.15 | |
| Capex to depreciation | -0.54 | -0.88 | |
| Stock based compensation to revenue | 0.39 | 16 | |
| Graham number | 22.26 | 63.61 | |
| ROIC | -0.07 | -0.37 | |
| Return on tangible assets | -0.07 | -0.36 | |
| Graham Net | 16.51 | 19.97 | |
| Working capital | 756.47M | 951.92M | |
| Tangible asset value | 0 | 895.51M | |
| Net current asset value | 733.56M | 865.61M | |
| Invested capital | 0 | 0.03 | |
| Average receivables | 82.65M | 43.8M | |
| Average payables | 6.35M | 7.31M | |
| Average inventory | 0 | 0 | |
| Days sales outstanding | 365 | 595.28 | |
| Days payables outstanding | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | |
| Receivables turnover | 1 | 0.61 | |
| Payables turnover | 0 | 0 | |
| Inventory turnover | 0 | 0 | |
| ROE | -0.07 | -0.41 | |
| Capex per share | -0.05 | -0.08 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.01 | 0.01 | 0 | 0 | 0 | |
| Net income per share | -0.66 | -0.73 | -0.57 | -0.71 | -0.76 | |
| Operating cash flow per share | -0.57 | -0.43 | -0.45 | -0.53 | -0.6 | |
| Free cash flow per share | -0.59 | -0.44 | -0.48 | -0.54 | -0.62 | |
| Cash per share | 6.65 | 10.34 | 8.29 | 7.71 | 9.5 | |
| Book value per share | 6.16 | 9.69 | 7.77 | 7.18 | 9.01 | |
| Tangible book value per share | 6.16 | 9.66 | 7.77 | 7.15 | 8.99 | |
| Share holders equity per share | 6.16 | 9.69 | 7.77 | 7.18 | 9.01 | |
| Interest debt per share | 0.25 | 0.25 | 0.21 | 0.21 | 0.56 | |
| Market cap | 2.92B | 2.85B | 3.24B | 1.82B | 2.48B | |
| Enterprise value | 2.72B | 2.59B | 3.14B | 1.73B | 2.19B | |
| P/E ratio | -12.01 | -10.55 | -13.06 | -5.92 | -7.37 | |
| Price to sales ratio | 4.39K | 5.02K | 7.74K | 4.99K | 7.21K | |
| POCF ratio | -54.94 | -71.69 | -65.91 | -31.87 | -37.51 | |
| PFCF ratio | -53.2 | -70.14 | -62.37 | -30.87 | -36.36 | |
| P/B Ratio | 5.12 | 3.17 | 3.85 | 2.33 | 2.48 | |
| PTB ratio | 5.12 | 3.17 | 3.85 | 2.33 | 2.48 | |
| EV to sales | 4.08K | 4.57K | 7.5K | 4.75K | 6.36K | |
| Enterprise value over EBITDA | -45.42 | -38.98 | -52.08 | -23.17 | -27.91 | |
| EV to operating cash flow | -51.08 | -65.21 | -63.94 | -30.37 | -33.06 | |
| EV to free cash flow | -49.46 | -63.8 | -60.5 | -29.42 | -32.04 | |
| Earnings yield | -0.02 | -0.02 | -0.02 | -0.04 | -0.03 | |
| Free cash flow yield | -0.02 | -0.01 | -0.02 | -0.03 | -0.03 | |
| Debt to equity | 0.04 | 0.02 | 0.02 | 0.03 | 0.05 | |
| Debt to assets | 0.15 | 0.11 | 0.11 | 0.12 | 0.14 | |
| Net debt to EBITDA | 3.43 | 3.87 | 1.61 | 1.15 | 3.76 | |
| Current ratio | 22.42 | 40.14 | 21.97 | 19.49 | 15.22 | |
| Interest coverage | 0 | 0 | -90.12 | -77.42 | -50.14 | |
| Income quality | 0.87 | 0.59 | 0.79 | 0.74 | 0.79 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 22.05 | 27.42 | 38.35 | 47.85 | 46.73 | |
| Research and developement to revenue | 67.53 | 91.55 | 123.31 | 165.78 | 194.48 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0.02 | 0.06 | 0.03 | 0.03 | |
| Capex to revenue | -2.61 | -1.55 | -6.67 | -5.09 | -6.09 | |
| Capex to depreciation | -1.72 | -0.85 | -2.87 | -1.94 | -2.03 | |
| Stock based compensation to revenue | 18.65 | 18.02 | 32.11 | 41.5 | 39.88 | |
| Graham number | 9.54 | 12.59 | 10.01 | 10.68 | 12.41 | |
| ROIC | -0.09 | -0.07 | -0.07 | -0.09 | -0.08 | |
| Return on tangible assets | -0.09 | -0.07 | -0.07 | -0.09 | -0.07 | |
| Graham Net | 5.61 | 9.18 | 7.33 | 6.74 | 8.01 | |
| Working capital | 610.74M | 951.92M | 874.1M | 811.89M | 1.02B | |
| Tangible asset value | 0 | 895.51M | 0 | 777.34M | 997.47M | |
| Net current asset value | 538.73M | 865.61M | 807.88M | 746.01M | 918.35M | |
| Invested capital | 0.04 | 0.03 | 0.03 | 0.03 | 0.06 | |
| Average receivables | 5.05M | 5M | 5M | 5.05M | 5.08M | |
| Average payables | 5.31M | 6.29M | 6.17M | 4.3M | 6.89M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 683.11 | 784.13 | 1.06K | 1.25K | 1.34K | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0.13 | 0.11 | 0.08 | 0.07 | 0.07 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.11 | -0.08 | -0.07 | -0.1 | -0.08 | |
| Capex per share | -0.02 | -0.01 | -0.03 | -0.02 | -0.02 |
RLAY Frequently Asked Questions
What is Relay Therapeutics, Inc. stock symbol ?
Relay Therapeutics, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol RLAY
Is Relay Therapeutics, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $23. The lowest prediction is $23 and the highest is $23
What is RLAY stock prediction ?
With a median analyst target price of $23, 1 stock analysts have made 1 forecasts in last 90 days. $23 is the lowest and $23 is the greatest projection.
What is Relay Therapeutics, Inc. stock quote today ?
Relay Therapeutics, Inc. stock price is $18.365 today.
Is Relay Therapeutics, Inc. stock public?
Yes, Relay Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.22M
- Market Capitalization 2.27B
- Employee 320
- CEO Mr. Alexis A. Borisy
- Headquarters Cambridge,MA,US
- IPO Date 2020-07-16
-
Website
https://www.relaytx.com 
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
